Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TT-034 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Escalating Dose of TT-034 | EXPERIMENTAL | The study contains one dose escalation arm with active drug. |
| Name | Type | Description |
|---|---|---|
| TT-034 | DRUG | The study drug will be given as a single dose IV infusion on Day 1. 5 different dose levels corresponding to the 5 cohorts of the study will be given. |
Inclusion Criteria: Subjects must a history of chronic HCV infection defined as documented HCV genotype 1 infection for at least 6 months. * Subjects must have: 1. Documented failure to respond to prior treatment or relapse with a combination of peg-interferon (peg-IFN), ribavirin (RBV), and ei...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | - | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Undisclosed |
TT-034 is an investigational small molecule being developed for the treatment of Hepatitis C. It is designed to target the hepatitis C virus and is currently in clinical development, having completed a Phase 1 trial in patients with chronic Hepatitis C.
TT-034 is being developed by Benitec Biopharma Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol BNTC.
TT-034 is in Phase 1 of clinical development. It has completed a Phase 1 trial, and it is important to note that it is still an investigational drug and has not been approved by regulatory authorities.
TT-034 has been studied in one clinical trial, identified as NCT01899092. This was a Phase 1, uncontrolled study titled 'Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C', which has been completed.
TT-034 is a small molecule that targets the hepatitis C virus. It is designed to interfere with the virus's replication process, thereby reducing viral load in patients with chronic Hepatitis C.